Manager, New Product Planning at Genesis Molecular AI (San Diego, CA)

Genesis Molecular AI· San Diego, CA· $85k–$115k·3d ago

Role details

Salary

$85k–$115k

Work type

Hybrid

Employment

Full-Time

Equity

Yes

Job description

The New Product Planning Manager is a high impact role that will support the strategy, planning and execution of commercial assessments for Genesis’s AI-enabled pipeline programs. The position will report to the Director of New Product Planning.

This role will be hybrid 2-3 days a week based at Genesis’s San Diego office.

Key Responsibilities:

Market analysis: Analyze disease areas, treatment paradigms, and unmet needs to help shape the positioning of new potential drugs
Primary and secondary research: Support KOL interviews, along with secondary research such as epidemiology and published literature, to build and validate commercial assumptions
Competitive monitoring: Track competitor pipelines, clinical readouts, approvals, and deals, including monitoring conference abstracts and presentations for early signals, and translate the implications into updated assumptions for the team
Development strategy: Contribute commercial input into Target Product Profiles (TPPs) and clinical development plans (endpoints, comparators, patient populations, and indication sequencing)
Cross-functional collaboration: Work with discovery, preclinical development, business development, and finance to keep programs aligned with commercial objectives

Candidate profile:

Life sciences background, ideally a BS or MS degree in biology or a related field
1-2 years at a top-tier consulting firm, investment bank, or equity research group preferred
Experience in New Product Planning, marketing, portfolio strategy, competitive intelligence, or a related analytical role at a pharmaceutical or biotech company also considered
Experience in oncology or immunology is a plus
Some exposure to commercial assessments based on primary and secondary research, ideally for preclinical and early clinical assets
Strong Excel modeling and PowerPoint skills
Excellent communication, listening, and presentation skills
Ability to travel domestically and internationally, if required, approximately 10% of the time

About Genesis Molecular AI

Genesis Molecular AI genesis.ml is pioneering foundation models for molecular AI to unlock a new era of drug design and development. Our generative and predictive AI platform, GEMS (Genesis Exploration of Molecular Space), integrates AI and physics into industry-leading models to generate and optimize drug molecules, including the breakthrough generative diffusion model Pearl businesswire.com for structure prediction. Genesis is backed by premier AI and life science investors, including a16z, NVIDIA, Rock Springs Capital, Menlo Ventures, T. Rowe Price, Fidelity, and Radical Ventures. Genesis has also signed category-leading AI-pharma deals, the most recent of which was a significant expansion with Incyte (see coverage in Forbes forbes.com and GEN genengnews.com) with a total potential deal value of several billion dollars.

Genesis is headquartered in San Mateo, CA, with a fully integrated laboratory in San Diego. We are proud to be an inclusive workplace and an Equal Opportunity Employer.

Why work at Genesis Molecular AI

Culture: Described as a “meritocracy of ideas” where the strongest ideas win through evidence and reasoning, not hierarchy. Values include ownership, experimentation, candor with kindness, curiosity, and collaboration across disciplines.
Work Environment: Flexible work environment with offices in Burlingame, San Diego, and New York. Daily meals and snacks provided in the office. Ergonomic consulting and equipment available.
Compensation & Benefits: Highly competitive compensation including base salary, bonus, and equity. Comprehensive health, dental, and vision insurance. Open PTO policy, parental leave, 401(k) retirement savings, financial planning resources.
Impact: Employees work on some of the hardest problems in drug discovery – applying cutting-edge AI to targets that are canonically undruggable, with the potential to create new treatment options for severe diseases.
Team Composition: The company actively hires across AI research, software engineering, molecular simulation, and drug discovery disciplines, fostering an interdisciplinary environment where researchers and drug hunters co-create daily.

About Genesis Molecular AI

Company Overview

One-liner: Genesis Molecular AI combines frontier AI research with deep drug discovery expertise to develop a proprietary platform (GEMS) that accelerates the design and optimization of small molecule medicines.
Entity Type: Private (Series B; raised over $300M in total funding)
Headquarters: Burlingame, California, United States (with a fully integrated laboratory in San Diego and offices in New York)
Founded: Not publicly disclosed (first major funding round – $200M Series B – closed in 2023)
Founders: Evan Feinberg Ph.D. (CEO, Co-founder) and Sergey Edunov (Co-founder); other key leaders include Will McCarthy (CTO) and Shifeng Pan Ph.D. (COO)

Core Business

Primary Industry: Biotechnology – AI-powered small molecule drug discovery.
Target Customers: Large pharmaceutical partners (B2B) via platform collaborations, plus an internal pipeline of wholly owned drug programs.
Mission/Purpose: “Solving the hardest problems in drug discovery to change the landscape of medicine” by creating and scaling domain-specific AI models that integrate physics, chemistry, biology, and software.

Products & Services

GEMS Platform: An AI operating system for molecular design. GEMS (Genesis Exploration of Molecular Space) integrates generative and predictive models to accelerate hit identification, lead optimization, and candidate selection. It is deployed for internal pipeline programs and major pharma collaborations.
Pearl Foundation Model: A generative foundation model for biomolecular structure prediction (protein-ligand) that demonstrated field-leading performance. Built in collaboration with NVIDIA and trained on large-scale synthetic data.
Internal Drug Pipeline: Small molecule inhibitors targeting oncology (e.g., pan-mutant allosteric PIK3CA inhibitors) and immunology (e.g., inflammatory signaling pathways). Programs are in discovery stage approaching development candidate nomination.
Platform Partnership Model: “Forward-deployed engineers and scientists” work alongside pharma partners (Gilead, Incyte) to apply GEMS to their targets, with deal structures that include upfront payments, milestones, and data sharing that feeds back into model training.

Market Standing

Valuation/Market Cap: Not disclosed.
Key Metric: Total funding raised >$300M (including $200M Series B in 2023 co-led by a16z, with participation from Fidelity, BlackRock, NVIDIA’s NVentures, Rock Springs Capital, T. Rowe Price, Radical Ventures, Menlo Ventures).
Notable Investors/Partners: Andreessen Horowitz, Fidelity, BlackRock, NVIDIA (NVentures), Rock Springs Capital, T. Rowe Price, Radical Ventures, Menlo Ventures. Pharma partners: Gilead ($35M upfront, 2024), Incyte ($150M total upfront including equity investment, 2025–2026).
Growth Signals: 125 employees (+26.4% YoY); operates in 7 countries; LinkedIn following grew 41.9% in the past year; Pearl model launched to strong benchmarking results; Incyte expanded collaboration with at least 5 additional targets and data for model training.

Competitive Advantages

Integration of disciplines: The company pairs leading AI researchers with world-class drug hunters, co-creating models and medicines in iterative loops.
Wet-lab flywheel: In-house lab in San Diego generates experimental data that closes the loop for model training, prediction, and validation – a virtuous cycle that strengthens the platform with every program.
Partnership data advantage: Deals with Gilead and Incyte provide significant proprietary experimental data (e.g., Incyte data for training GEMS), creating a moat that is hard for pure-play AI companies to replicate.
Domain-specific foundation models: Models like Pearl are purpose-built for small molecule drug discovery, unlike general-purpose generative AI.

Strategic Focus

Advancing internal pipeline: Moving lead programs in oncology (PIK3CA, apoptosis) and immunology toward development candidate nomination.
Scaling platform partnerships: Expanding existing collaborations and signing new ones to broaden the impact of GEMS and generate more training data.
Continuous model improvement: Investing in next-generation foundation models (e.g., Pearl) and leveraging partner data to stay at the frontier of molecular AI.
Hiring across AI and drug discovery: Open roles for machine learning research scientists, software engineers, computational chemists, medicinal chemists, and biologists indicate a focus on scaling both the tech and biology teams.

Sources

Job description

About Genesis Molecular AI

Why work at Genesis Molecular AI

Application questions